Spyre Therapeutics (SYRE)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Spyre Therapeutics, with a price target of $128.00. The company’s shares closed last Friday at $104.91.
According to TipRanks.com, Slutsky is a top 100 analyst with an average return of 52.6% and a 57.1% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ArriVent BioPharma, Inc., and Abivax SA Sponsored ADR.
Currently, the analyst consensus on Spyre Therapeutics is a Strong Buy with an average price target of $118.09, an 11.4% upside from current levels. In a report issued on July 25, TipRanks – PerPlexity also upgraded the stock to Buy with a $110.00 price target.
See today’s best-performing stocks on TipRanks >>
